class i hdac inhibitor hdaci valproate (Sanofi)
Structured Review

Class I Hdac Inhibitor Hdaci Valproate, supplied by Sanofi, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/class+i/hdac+hdaci+inhibitor+valproate/pmc13201554-277-40-52
Average 86 stars, based on 1 article reviews
Images
1) Product Images from "Insulin enables acquisition of the IL7R + memory phenotype in PD1 + T cells in RA tissues"
Article Title: Insulin enables acquisition of the IL7R + memory phenotype in PD1 + T cells in RA tissues
Journal: Cell Death & Disease
doi: 10.1038/s41419-026-08916-6
Figure Legend Snippet: A Glucose metabolism. Studied metabolic pathways are in bold. B Box plots of standardized expression sum (SES), by RNA-seq, of genes within metabolic pathways in CD4 + cells of RA ( n = 11), healthy controls (HC, n = 57), and of CD4 + cells split by mean expression of BIRC5 gene in high (B5 hi ) and low (B5 lo ) ( n = 24). Boxes indicate IQR and whiskers indicate the minimum and maximum values. GO-terms used for pathway annotation: Glycolysis (GO:0006096); oxidative phosphorylation (OxPhos, GO:0006119 and GO:0022900); pentose phosphate pathway (PPP, GO:0006098); tricarboxylic acid cycle (TCA, GO:0006099). P -values are calculated by Wilcoxon unpaired test. C Heatmap of Spearman’s correlation between HAT, HDAC and metabolic pathways as above. GO-terms used for annotation HAT (GO:0000123) and HDAC (GO:0000118). Asterisks indicate p -values. * < 0.05, ** < 0.01, *** <0.001. D Heatmap of Spearman’s correlation between HAT and HDAC and insulin signaling (IS). Asterisks indicate p -values * < 0.05, ** < 0.01, *** <0.001. E Scatter plot of Spearman’s correlation between plasma insulin levels and SES of insulin signaling. F Uniform manifold approximation and projection (UMAP) map of scaled expression intensity of BIRC5 , IFNG , and TNF in T cells of RA synovial tissue (ST), by single cell transcriptome. BIRC5 Hi CD4 + clusters are indicated. G Heatmap of scaled expression intensity of metabolic pathway (annotated as above) in peripheral blood (PB), synovial fluid (SF), and ST of RA patients, by scRNA-seq. H Violin plot of insulin signaling by SES of INSR, IRS1, IRS2 and IGF1R genes in BIRC5 Hi CD4 + clusters. P-value was calculated by chi-square test. I Violin plot of metabolic pathways SES in cells with high and low IS in BIRC5 Hi CD4 + clusters. P -values are calculated by Wilcoxon unpaired test. Asterisks indicate * < 0.05, ** < 0.01, *** <0.001, **** <0.0001 J . Box plot of BIRC5, IFNG , and TNF expression in Tph cells with high and low IS. Boxes indicate IQR and whiskers indicate the minimum and maximum values. P -values are calculated by Wilcoxon unpaired test. K Heatmap of expression for IL7R-signaling targets in Tph cells high and low IS. Genes regulated by survivin-H3K27ac are in bold. P -values are calculated by Wilcoxon unpaired test. Asterisks indicate * < 0.05, ** < 0.01, *** <0.001, **** <0.0001.
Techniques Used: Expressing, RNA Sequencing, Phospho-proteomics, Clinical Proteomics, Single Cell
Figure Legend Snippet: A Confocal microscopy images of THP1 cells stained with antibodies to H3K27ac (red) in nucleus (blue) after stimulation with insulin (top), and HDAC-inhibitor (bottom) for 24 h. Images are acquired with 40× magnification with additional digital magnification 1.5×. B Scatter plot of nuclear H3K27ac staining intensity after stimulation with insulin (top) and HDAC-inhibitor (bottom). P -values are calculated by Wilcoxon unpaired test. Asterisks indicate * < 0.05, ** < 0.01, *** <0.001, **** <0.0001. C Histogram of phosphorylated serine 473 (p)AKT1 mean fluorescence intensity in THP1 cells stimulated with 10 nM insulin, by flow cytometry. D Histogram of H3K27ac mean fluorescence intensity in THP1 cells stimulated with increasing concentrations of insulin for 24 h, by flow cytometry. E Histogram of pAKT1 mean fluorescence intensity in human lymphocytes stimulated with increasing concentrations of insulin for 30 min, by flow cytometry.
Techniques Used: Confocal Microscopy, Staining, Fluorescence, Flow Cytometry
Figure Legend Snippet: A Analysis strategy of survivin and H3K27ac deposition, by ChIP-seq, in cis-regulatory elements ( cis -RE) and connected genes in human CD4 + T cells. B Venn diagram of insulin-responsive (InsResp) genes connected to cis -RE with survivin-H3K27ac co-deposition. Genes are identified by DESeq2 analysis of CD4 + cells transcriptome after a) direct insulin stimulation (InsStim) and b) in regression to corresponding plasma insulin levels, by RNA-seq. C Scatter plot of pathway enrichment of insulin-responsive genes, by GSEA GO-terms. Circle size indicates the number of genes in the pathway, and color intensity indicates p -value. D Venn diagram of insulin-responsive (InsResp) genes connected to cis -RE with H3K27ac deposition. Genes are identified by DESeq2 analysis of CD4 + cells transcriptome after a) direct insulin stimulation (InsStim) and b) HDAC inhibition. E Scatter plot of protein subunits with survivin-H3K27ac in HAT (E1) and HDAC (E3) complexes, annotated by STRING database. Circle size represents number of cis- RE with survivin-H3K27ac connected to the gene. Circle color represents beta-coefficient of expression difference by DESeq2 analysis of CD4 + cell transcriptome in regression to corresponding plasma insulin levels. (E2 and E4) Heatmap of transcription difference, by log2FoldChange (FC), in CD4 + cells in regression to plasma insulin levels (InsReg), and after HDAC inhibitor treatment in vitro. F . Bar plot of percentage of H3K27ac and survivin-H3K27ac connected genes in each metabolic pathway. GO-terms used for pathway annotation as in Fig. . G Scatter plot of expression difference of survivin-H3K27ac connected genes in transcriptome of CD4 + cells in regression to plasma insulin levels and after HDACi treatment, by RNA-seq. Expression difference is calculated by DESeq2 analysis. Colour fill corresponds to metabolic pathway annotation of the gene.
Techniques Used: ChIP-sequencing, Clinical Proteomics, RNA Sequencing, Inhibition, Expressing, In Vitro
Figure Legend Snippet: A Transition model of PD1 hi Tph cells to the IL7R + T memory cells, influenced by insulin and HDAC inhibition. B Box plot of protein cytokine levels in supernatants of CD4 + cells ( n = 12) stimulated with insulin (25 nM) and HDACi (50 µg/mL) for 24 h, by ELISA. Boxes indicate IQR and whiskers indicate the minimum and maximum values. P -values are calculated by Wilcoxon Sign rank test. C Gating strategy to CD4 + T cell subset analysis by flow cytometry. D Box plot of PD1 and CD27 expression in CD4 + cells ( n = 8) stimulated by insulin and HDACi, by mean fluorescence intensity (MFI). Boxes indicate IQR and whiskers indicate the minimum and maximum values. P -values are calculated by Wilcoxon Sign rank paired test. E Heatmap of expression difference of IL7R-related signaling molecules in CD4 + cells after in vitro stimulation with insulin (25 nM), HDACi (50 µg/mL), IFNγ (50 ng/ml), and survivin inhibitor YM155 (10 μM), by RNA-seq. Genes connected to cis -RE containing survivin-H3K27ac co-deposition are indicated bold. Asterisks indicate RNA-seq p -values * < 0.05, ** < 0.01, *** <0.001, **** <0.0001. F Heatmap showing expression difference, by log2FC, of cluster markers of Tph cluster after insulin stimulation, HDAC inhibition. In bold are the genes supervised by a cis-RE containing survivin-H3K27ac deposition. P -values are calculated by DESeq2 analysis. Asterisks indicate nominal p -values * < 0.05, ** < 0.01, *** <0.001, **** <0.0001.
Techniques Used: Inhibition, Enzyme-linked Immunosorbent Assay, Flow Cytometry, Expressing, Fluorescence, In Vitro, RNA Sequencing
Related Articles
other:Article Title: Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development. Article Snippet: Dengue is a re-emerging arboviral disease of great public health importance.. Limited understanding of protective immune responses against dengue has hampered advancement of dengue vaccine candidates.. Demonstrating an immunological correlate of protection has been limited to associating quantitative neutralizing antibody titers with clinical outcomes following infection. Article Title: Riferminogene pecaplasmide. Article Snippet: Sanofi-aventis is developing riferminogene pecaplasmide, a fibroblast growth factor 1 (FGF-1; NV1FGF) gene therapy for the treatment of peripheral arterial disorders (PAD) such as critical limb ischemia.. Following intramuscular injection into an area of restricted blood flow, riferminogene pecaplasmide is taken up by muscle cells resulting in increased expression of FGF protein, which in turn promotes blood vessel growth.. Riferminogene pecaplasmide is currently being evaluated in a randomized, double-blind, placebo-controlled phase III trial (TAMARIS) in patients with PAD in 32 countries, including the US, EU, Canada, Japan and Australia. Article Title: Correct stimulation of CD28H arms NK cells against tumor cells. Article Snippet: Article Title: Review of companies and drug classes in the 2007-2011 antihypertensive patent literature. Article Snippet: 1Department of Worldwide Medicinal Chemistry, Cardiovascular & Metabolic Diseases, Pfizer PharmaTherapeutics, 620 Memorial Drive, Cambridge, MA 02139, USA 2Department of Drug Safety Research & Development, Pfizer Worldwide Research & Development, Eastern Point Rd, Groton, CT 06340, USA *Author for correspondence: Tel.. : +1 617 551 3235 E-mail: philip.a.carpino@pfizer.com Hypertension, defined as elevated systolic blood pressure and/or diastolic blood pressure generally greater than 140/90 mmHg, is a significant risk factor for cardiovascular outcomes such as arterial aneurysm, myocardial infarction and stroke, and for nonvascular conditions such as Alzheimer’s disease.. The prevalence of the disease is rapidly increasing both in the USA and in the rest of the world. Flow Cytometry:Article Title: Insulin enables acquisition of the IL7R + memory phenotype in PD1 + T cells in RA tissues Article Snippet: PBMC cultures (1 ×10 6 cells/mL) in RPMI medium (Gibco, Waltham, Massachusetts, USA) containing 50 μM β-mercaptoethanol (Gibco), Glutamax 2 mM (Gibco), gentamicin 50 μg/mL (Sanofi-Aventis) and 5% fetal bovine serum (Sigma-Aldrich) at 37 °C in a humidified 5% CO 2 atmosphere. .. Cells were stimulated with concanavalin A (ConA, 0.625 μg/mL, MP Biomedicals), and lipopolysaccharide (LPS, 5 μg/mL, Sigma-Aldrich) for 48 h. For immunophenotyping, the cultures were supplemented with insulin (Humalog 100 U/mL, Eli Lilly, Indianapolis, IN, USA) 25 nM and/or the Histone Deacetylase Assay:Article Title: The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo Article Snippet: Interleukin-6 (rh-IL6) was from PeproTech. .. The histone deacetylase-like (HDAC) inhibitor, |